UroGen reports data from Phase IIb trial of bladder cancer treatment

UroGen Pharma has reported the latest findings from the Phase IIb OPTIMA II clinical trial of its investigational drug, UGN-102 (mitomycin), to treat low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMIBC).